Sarepta Therapeutics (SRPT) Tops Q2 EPS by 92c

Sarepta Therapeutics (NASDAQ: SRPT) reported Q2 EPS of ($0.85), $0.92 better than the analyst estimate of ($1.77). Revenue for the quarter came in at $261.2 million versus the consensus estimate of $259.79 million.

For earnings history and earnings-related data on Sarepta Therapeutics (SRPT) click here.

You May Also Be Interested In

• Etsy upgraded to buy at BofA on durable growth, buyback potential
• Advance Auto Parts falls on revenue miss, weak guidance
• SentinelOne Inc (S) PT Raised to $26 at Cantor Fitzgerald Following Strong Q2 Checks